O3R-5671
/ Onco3R Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 14, 2026
The First-in-Class SIK3 Inhibitor O3R-5671 Demonstrates Optimal Pharmacokinetics and Potent and Sustained Pharmacodynamic Activity in Human Participants
(ECCO-IBD 2026)
- No abstract available
PK/PD data • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1